Enanta Pharmaceuticals price to free cash flow ENTA

Market value divided by free cash flow over the last twelve months, since 2014.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 189×; Feb 2021
10-year median: 29.6×
10-year range: 13.6× to 189×
Peer median: 9.4×

Enanta Pharmaceuticals' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Feb 2021, at 189×.

On the days it had one over the last ten years, its median was 29.6×, from 13.6× in Oct 2019 to 189× in Feb 2021.

Price to free cash flow over time

median 29.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	189×	162×	189×
2020	150×	15.4×	157×
2019	18.7×	13.6×	67.1×
2018	51.9×	22.2×	58.6×
2017	22.4×	19.7×	111×
2016	20.5×	4.4×	27.1×
2015	8.3×	5.8×	49.0×
2014	50.2×	33.5×	50.2×

Against its peers

Companies in Drug Manufacturers - General nearest Enanta Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
ENTAEnanta Pharmaceuticals	n/m
ARVNArvinas	n/m
NATRNatures Sunshine Products	11.8×
PBYIPuma Biotechnology	13.8×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	17.9×
CRMDCorMedix	2.4×
COLLCollegium Pharmaceutical	2.3×
ABUSArbutus Biopharma	n/m
AMPHAmphastar Pharmaceuticals	7.0×
OMEROmeros	n/m
Peer median	9.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Enanta Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.